H.C. Wainwright analyst Yi Chen reiterated a Hold rating on Aerpio Pharmaceuticals (NASDAQ:ARPO) Inc on Monday, setting a price target of $1, which is approximately 58.73% above the present share price of $0.63.
Chen expects Aerpio Pharmaceuticals Inc to post earnings per share (EPS) of -$0.11 for the second quarter of 2020.
The current consensus among 1 TipRanks analysts is for a Hold rating of shares in Aerpio Pharmaceuticals, with an average price target of $1.
The analysts price targets range from a high of $1 to a low of $1.
In its latest earnings report, released on 12/31/2019, the company reported a quarterly revenue of $0 and a net profit of -$3.63 million. The company's market cap is $25.59 million.
According to TipRanks.com, H.C. Wainwright analyst Yi Chen is a 5-star analyst with an average return of 17.3% and a 44.8% success rate.
Aerpio Pharmaceuticals Inc. is a biopharmaceutical company, which engages in the research and development of treatments for ocular diseases. Its product candidate is AKB-9778, a small molecule activator of the Tie2 pathway, which completed the Phase 2a clinical trial for the treatment of diabetic retinopathy. It also develops ARP-1536, a humanized monoclonal antibody that is in preclinical development stage for the treatment of diabetic vascular complications; and AKB-4924, a selective stabilizer of hypoxia-inducible factor-1 alpha, which has completed a single ascending dose clinical trial for the treatment of inflammatory bowel disease. The company was founded by Joseph H. Garder on November 17, 2011 and is headquartered in Cincinnati, OH.